Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Metastatic Breast Cancer: A Meta-Analysis
- 주제(키워드) paclitaxel , metastatic breast cancer , nanoparticle albumin-bound
- 주제(기타) Medicine, General & Internal
- 설명문(일반) [Li, Xin; Kwon, Hyungju] Ewha Womans Univ, Dept Surg, Med Ctr, 1071 Anyangcheon Ro, Seoul 07985, South Korea
- 등재 SCIE, SCOPUS
- OA유형 Green Published, gold
- 발행기관 MDPI
- 발행년도 2019
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000165932
- 본문언어 영어
- Published As http://dx.doi.org/10.3390/jcm8101689
- PubMed https://pubmed.ncbi.nlm.nih.gov/31618921
초록/요약
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is an approved treatment for metastatic breast cancer (MBC). However, there is an ongoing debate about the efficacy and safety of nab-paclitaxel in elderly patients. We conducted a meta-analysis to evaluate nab-paclitaxel efficacy and adverse events in MBC patients 65 years and older, compared with MBC patients younger than 65 years (control group). We performed a literature search using PubMed, the Cochrane Library, and EMBASE, from their inception to 30 September 2019. The relevant studies compared overall response rates (ORRs) and incidence of adverse events; four studies comprising 1204 patients were identified and included. ORRs were similar in patients older than 65 years and controls (odds ratio (OR) 0.71, 95% confidence interval (CI) 0.42-1.21). On subgroup analysis, both first-line therapy (OR 2.54, 95% CI 1.92-3.36) and lower Eastern Cooperative Oncology Group (ECOG) performance status (OR 0.20, 95% CI 0.06-0.69) were associated with a higher ORR. Adverse events including neutropenia, sensory neuropathy, diarrhea, and nausea were comparable between the groups. In conclusion, nab-paclitaxel showed comparable efficacy and safety in older and younger patients with MBC. Nab-paclitaxel can be a first-line treatment option for MBC patients 65 years and older.
more